---
title: "Advanced Drug Delivery Strategies for Overcoming Biological Barriers: Tumor Microenvironment and Blood-Brain Barrier."
description: "Therapeutic efficacy for malignancies and neurological disorders is fundamentally restricted by biological barriers, particularly the complex tumor microenvironment (TME) and selective blood-brain barrier (BBB). This review analyzes advanced drug del..."
date: "2026-03-01"
category: "investigacion"
pubmedId: "41764714"
author: "Yicong Lei, Tingyu Xiao, Xin Hu et al."
tags: []
---

## Resumen

Therapeutic efficacy for malignancies and neurological disorders is fundamentally restricted by biological barriers, particularly the complex tumor microenvironment (TME) and selective blood-brain barrier (BBB). This review analyzes advanced drug delivery technologies engineered to overcome these obstacles. For TME penetration, stimuli-responsive nanocarriers enable spatiotemporally controlled drug release, while tumor-penetrating peptide functionalized nanoparticles enhance deep tumor diffusion; metal-organic frameworks further facilitate combinatorial therapy via microenvironment-triggered payload release. Regarding BBB transcendence, receptor-mediated transcytosis strategies significantly improve brain uptake, and physical-assisted approaches achieve localized barrier modulation. Bioinspired platforms-notably cell-membrane-coated nanoparticles and exosomes-demonstrate superior immune evasion and tissue-specific accumulation. Despite promising clinical progress exemplified by ANG1005 and focused ultrasound-assisted liposomal doxorubicin, translation challenges persist, including TME heterogeneity, scalable manufacturing complexities, and long-term biosafety. Future development prioritizes multifunctional theranostic systems integrating barrier-remodeling agents, artificial intelligence (AI)-optimized nanocarrier design, and sustainable manufacturing processes. Collectively, these innovations are transforming advanced drug delivery into a core therapeutic paradigm for intractable diseases.

## Información del artículo

- **Revista:** Drugs in R&amp;D
- **Fecha de publicación:** 2026-03-01
- **Autores:** Yicong Lei, Tingyu Xiao, Xin Hu, Huaqing Lin
- **DOI:** [10.1007/s40268-026-00538-9](https://doi.org/10.1007/s40268-026-00538-9)
- **PubMed ID:** [41764714](https://pubmed.ncbi.nlm.nih.gov/41764714/)

## Referencias

Este artículo fue obtenido automáticamente desde [PubMed](https://pubmed.ncbi.nlm.nih.gov/41764714/), la base de datos de literatura biomédica del National Center for Biotechnology Information (NCBI).
